4CLL8 Antibody

Potential Candidates with Similar Nomenclature

Antibodies containing "4C" or "4CL" in their identifiers are reviewed here for contextual relevance:

4C8 Antibody (Clone 1HU-4C8)

• Target: Huntingtin protein (associated with Huntington’s disease) .

• Epitope: Mapped to amino acids 443–457 of human huntingtin, with critical glutamic acid residues at positions 443–445 .

• Applications:

  • Western blotting (detects huntingtin in brain lysates) .

  • Immunohistochemistry and immunoprecipitation .

• Commercial Availability: Sold by Merck Millipore (MAB2166) and Thermo Fisher (MA3-040) .

4C4 Antibody (LOS 4C4)

• Target: Lipooligosaccharide (LOS) of Neisseria gonorrhoeae and N. meningitidis .

• Applications:

  • ELISA, Western blot, immunofluorescence.

  • Validated for use in detecting bacterial LOS in clinical samples .

4G8 Antibody

• Target: Amyloid-beta (Aβ) peptide (residues 18–23) .

• Role: Detection of Aβ aggregates in Alzheimer’s disease research.

• Conjugate: SULFO-TAG™ for electrochemical luminescence assays .

Comparative Analysis of Antibody Features

1HU-4C8 in Neurodegenerative Disease

• Function: Detects both wild-type and mutant huntingtin, aiding in Huntington’s disease (HD) research .

• Key Finding: N-terminal fragments of mutant huntingtin are cytotoxic, and 1HU-4C8 helps quantify these fragments in preclinical models .

LOS 4C4 in Infectious Disease

• Utility: Critical for identifying Neisseria strains in meningitis and gonorrhea diagnostics .

• Specificity: Binds to heat-killed gonococcal strain 4505 cells with high affinity .

4G8 in Alzheimer’s Research

• Assay Use: SULFO-TAG™ conjugation enables ultrasensitive Aβ detection in cerebrospinal fluid .

Hypothetical Context for "4CLL8"

If "4CLL8" refers to an antibody targeting CCR8 (a chemokine receptor implicated in cancer immunotherapy), recent studies describe bispecific antibodies like 2MW4691 (CCR8/CTLA-4) with the following properties :

• Structure: Tetravalent symmetric format.

• Activity:

  • Depletes tumor-infiltrating regulatory T cells (Tregs) via ADCC/ADCP.

  • Enhances CD8+ T cell activation .

• Preclinical Data:

  • EC50: 0.2 nM for CCR8 binding.

  • Tumor Growth Inhibition: 78% reduction in murine models .